CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)-- Anji Pharma (“Anji”) has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease. As part of Anji’s global clinical study program, called “DREAM-T2D,” patients with T2D having normal kidney function to Stage 3B chronic kidney disease (CKD) will be enrolled for as long as 52 weeks and assessed for HbA1c levels throughout the treatment period. Despite being the mainstay of oral T2D therapy, metformin is contraindicated in T2D patients with advanced CKD due to a rare but potentially life-threatening side effect called lactic acidosis. Without metformin, T2D patients with advanced CKD often require high doses of insulin to achieve glucose control, which can increase the risk of severe hypoglycemia. Based on recent evidence that metformin’s glucose-lowering effects are largely attributed to direct action at the gut wall, Anji is developing a gut-targeted metformin for use in T2D patients with kidney disease. Anji’s DREAM-T2D study includes clinical sites in North America, Europe, Asia, and Latin America. In launching DREAM-T2D, Anji has operationalized its “hub-and-spoke" model to insource core clinical, regulatory, and manufacturing expertise whilst achieving scale through close partnership with the drug development business of Labcorp, a leading global life sciences company. “Successfully launching an international, multi-center, pivotal trial amidst a global pandemic is a tremendous accomplishment for both the Anji and Covance by Labcorp teams,” noted Greg Dombal, Global Head of Development at Anji. “We feel fortunate that Covance by Labcorp embodies several core Anji values—be good partners and act with urgency—so that we may rapidly deliver medicine to patients across the globe.” “Improving the lives of diabetics with renal disease is more than just a laudable goal, it’s an achievable one,” said Honggang Bi, Ph.D., Senior Vice President and Head of APAC at Covance by Labcorp. “This new partnership underscores our commitment to patients with T2D and CKD and marks a meaningful step forward in their fight.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!